Shots:

• Sanofi to acquire Tidal Therapeutics for $160M up front and ~ $310M following the achievement of certain milestones
• The acquisition will add Tidal’s innovative mRNA-based research platform with applications in oncology- immunology- and other disease areas
• With its acquisition- Sanofi will further develop the technology platform to expand its research capabilities in immuno-oncology and inflammatory diseases. The technology platform has the potential to bring CAR-T cell therapy to a broader population

  Ref: GlobeNewswire | Image: MedCity News